SEC Form 4 · accession 0001209191-18-029995
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Apple
Officer — President & CEO · Director
Period of report
May 11, 2018
Accepted (ET)
May 14, 2018 · 6:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 11, 2018 | M | 82,500 | $0.85 | A | 1,334,971 | D | |
| Common StockF1 | May 11, 2018 | F | 30,052 | $2.52 | D | 1,304,919 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.85 | May 11, 2018 | M | 82,500 | D | — | May 13, 2018 | Common Stock | 82,500 | 0 | D |
Explanation of responses
- F1Represents shares used to cover payment of exercise price and tax liability for the underlying stock options that were exercised and held.
- F2The options vested in equal quarterly installments over the three-year period following the grant date of May 14, 2008, and were due to expire on May 13, 2018.